TARS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tarsus Pharmaceuticals Inc (TARS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong revenue growth, increasing hedge fund interest, and positive analyst sentiment outweigh the short-term technical weaknesses. The lack of significant news or congress trading data does not detract from the long-term growth potential highlighted by analysts.
The MACD is negative and expanding (-0.52), indicating bearish momentum. RSI is neutral at 30.344, and moving averages are converging, suggesting indecision. The stock is trading near its S1 support level (68.841), which could act as a short-term floor.
Hedge fund buying has surged by 987.14% in the last quarter, signaling institutional confidence. Analysts have raised price targets significantly, with projections as high as $105, citing strong revenue growth and market penetration potential for XDEMVY.
Technical indicators suggest short-term bearish momentum. The stock's MACD is negative, and it is trading near its support level, indicating potential downside risk in the short term.
In Q4 2025, revenue increased by 128.39% YoY to $151.67M, driven by strong product sales. However, net income dropped by -63.77% YoY to -$8.37M, and EPS fell by -66.67% YoY to -0.2. Despite these declines, gross margin improved slightly to 92.8%.
Analysts are highly optimistic, with multiple firms raising price targets. Oppenheimer raised its target to $105, citing strong sales guidance and market potential for XDEMVY. Guggenheim and BofA also raised targets to $90, highlighting sustained growth prospects.
